R-bambuterol - Lotus Pharmaceuticals

Drug Profile

R-bambuterol - Lotus Pharmaceuticals

Alternative Names: Laevo bambuterol

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong Guan Kai Fa Biologicals Medicine
  • Developer Lotus Pharmaceuticals
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (PO, Tablet)
  • 27 Oct 2010 State Food and Drug Administration approves phase I pharmacokinetic trial of R-bambuterol in healthy volunteers in China
  • 26 Aug 2010 Phase-I clinical trials in Asthma (in volunteers) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top